Literature DB >> 9777898

Four decades of therapy for AML.

E J Freireich1.   

Abstract

A review of the last four decades of leukemia research and treatment provides a view toward the next four decades. What is learned in leukemia research may apply to the treatment of other cancers. The biology of cancer, the importance of chromosomes, and the suppressor genes may hold the answers to future treatments.

Entities:  

Mesh:

Year:  1998        PMID: 9777898

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  Supportive care in patients with acute leukaemia: historical perspectives.

Authors:  Giovanna Cannas; Xavier Thomas
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Authors:  F Giles; J Cortes; G Garcia-Manero; S Kornblau; E Estey; M Kwari; A Murgo; H Kantarjian
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.

Authors:  Limin Liu; Yanming Zhang; Zhengming Jin; Xingxia Zhang; Guangsheng Zhao; Yejun Si; Guoqiang Lin; Aidi Ma; Yingxin Sun; Li Wang; Depei Wu
Journal:  Int J Hematol       Date:  2014-03-13       Impact factor: 2.490

Review 4.  A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Guoqing Wei; Wanmao Ni; Jen-wei Chiao; Zhen Cai; He Huang; Delong Liu
Journal:  J Hematol Oncol       Date:  2011-11-14       Impact factor: 17.388

5.  HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.

Authors:  Mixue Xie; Qi Jiang; Li Li; Jingjing Zhu; Lixia Zhu; Yanlong Zheng; Xiudi Yang; Mingyu Zhu; Jianai Sun; Wanzhuo Xie; Xiujin Ye
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.